Organogenesis (ORGO) VP updates Form 4 for award vesting and tax shares

Rhea-AI Filing Summary

Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares acquired upon vesting and settlement of a performance share award and the shares withheld for taxes. On February 18, 2026, he was granted 16,454 shares at $0.00 per share and had 5,487 shares withheld at $3.84 per share to satisfy tax obligations. Following these adjustments, his direct holdings total 276,224 Class A shares. The filing states no other changes were made to the original report.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Cavorsi Robert

Role Vice President, Strategy

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	16,454	$0.00	--
Tax Withholding	Class A Common Stock	5,487	$3.84	$21K

Holdings After Transaction: Class A Common Stock — 281,711 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cavorsi Robert

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Strategy

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A		16,454(1)	A	$0	281,711	D
Class A Common Stock	02/18/2026		F		5,487(1)	D	$3.84	276,224	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.

	/s/ William R. Kolb, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the amended Form 4 for Organogenesis (ORGO) report about Robert Cavorsi?

The amended Form 4 updates share counts for Robert Cavorsi’s equity award. It corrects the number of Organogenesis Class A shares acquired from a performance share vesting and the number withheld to cover related tax obligations, without introducing any new transactions.

How many Organogenesis (ORGO) shares did Robert Cavorsi acquire in the corrected filing?

The amended filing reports that Robert Cavorsi acquired 16,454 shares of Organogenesis Class A Common Stock. These shares were received at $0.00 per share upon the vesting and settlement of a performance share award granted as part of his compensation.

How many Organogenesis (ORGO) shares were withheld for taxes in Cavorsi’s amended Form 4?

The amendment shows that 5,487 Organogenesis Class A shares were disposed of to satisfy tax obligations. These shares were withheld at a price of $3.84 per share, reflecting a tax-withholding disposition rather than an open-market sale by the executive.

What is Robert Cavorsi’s Organogenesis (ORGO) share ownership after the amended transactions?

After the corrected grant and tax-withholding entries, Robert Cavorsi directly holds 276,224 shares of Organogenesis Class A Common Stock. This figure reflects his updated ownership position following the vesting of the performance share award and related tax-share withholding.

Does the Organogenesis (ORGO) amended Form 4 add any new insider trades?

The amended Form 4 does not add new trades; it only corrects share counts. It clarifies the number of shares acquired through a performance share vesting and the number withheld for taxes, with no other changes to the originally reported transactions.

Why was the original Organogenesis (ORGO) Form 4 for Robert Cavorsi corrected?

The original Form 4 was corrected because it misstated the shares tied to a performance award. The amendment fixes the number of shares acquired on vesting and those withheld for tax obligations, while explicitly noting that no other aspects of the filing were changed.